First-line treatment for locally advanced or metastatic urothelial carcinoma: a randomized controlled phase III study comparing pembrolizumab with and without platinum-based combination chemotherapy and chemotherapy alone in patients with advanced or metastatic urothelial carcinoma (Keynote-361) AB 54/16 of AUO

被引：0
|
作者：
Rexer, H. [1 ]
Ohlmann, C. -H. [2 ]
Retz, M. [3 ]
机构：
[1] AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Arbeitsgemeinschaft Urol Onkol Deutsch Krebsgesel, Organgrp Blasenkarzinom, Kuno Fischer Str 8, D-14057 Berlin, Germany
[3] Tech Univ Munich, Urol Klin & Poliklin, LKP, Klinikum Rdl, Ismaninger Str 22, D-81675 Munich, Germany
来源：
AKTUELLE UROLOGIE | 2018年 / 49卷 / 01期
关键词：
D O I：
10.1055/s-0043-125341
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [31] Phase III study of first-line pembrolizumab (pembro) plus lenvatinib (len) in patients (pts) with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy: LEAP-011
    Loriot, Yohann
    Balar, Arjun Vasant
    De Wit, Ronald
    Garcia, Jorge A.
    Grivas, Petros
    Matsubara, Nobuaki
    Moreno, Blanca Homet
    Sbar, Eric
    Jia, Xieyang Calvin
    Dutcus, Corina E.
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [32] Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy
    Joaquim Bellmunt
    Chensheng Willa Zhou
    Stephanie A Mullane
    Lillian Werner
    Mary-Ellen Taplin
    André P Fay
    Toni K Choueiri
    Anna Orsola
    David Y Takeda
    William C Hahn
    Jaegil Kim
    Guru Sonpavde
    Michaela Bowden
    British Journal of Cancer, 2016, 115 : 12 - 19
  • [33] First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma
    Lin, Zuan
    Fu, Sha
    Zhou, Yixin
    Zhang, Xuanye
    Chen, Chen
    He, Li-na
    Li, Haifeng
    Wang, Yuhong
    Chen, Tao
    Zhang, Li
    Hong, Shaodong
    LUNG CANCER, 2019, 137 : 100 - 107
  • [34] PEMBROLIZUMAB VS. CONVENTIONAL CHEMOTHERAPY AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED UROTHELIAL CARCINOMA IN REAL-WORLD PRACTICE: A MULTICENTER RETROSPECTIVE STUDY
    Narita, Takuma
    Hatakeyama, Shingo
    Numakura, Kazuyuki
    Kobayashi, Mizuki
    Muto, Yumina
    Saito, Mitsuru
    Narita, Shintaro
    Tanaka, Toshikazu
    Noro, Daisuke
    Tokui, Noriko
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Habuchi, Tomonori
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2021, 206 : E767 - E767
  • [35] A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
    Powles, T. B.
    van der Heijden, M. S.
    Castellano Gauna, D.
    Loriot, Y.
    Galsky, M. D.
    Petrylak, D. P.
    Ogawa, O.
    Park, S. H.
    Necchi, A.
    Lee, J-L.
    De Giorgi, U.
    Boegemann, M.
    Bamias, A.
    Fay, A. P.
    Duran, I.
    Angra, N.
    Gupta, A. K.
    He, P.
    Levin, W.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S550 - S551
  • [36] Real-world survival and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma treated with second-line therapy after platinum-based chemotherapy
    Simeone, Jason C.
    Nordstrom, Beth L.
    Patel, Ketan
    Klein, Alyssa B.
    Horne, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [37] Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.
    Powles, Thomas
    Bellmunt, Joaquim
    Petrylak, Daniel Peter
    Fong, Lawrence
    Nishiyama, Hiroyuki
    Sternberg, Cora N.
    Chen, Mei
    Pang, Lei
    Munteanu, Mihaela
    Zhao, Yufan
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Real world progression-free survival in patients with advanced or metastatic urothelial cancer treated with first-line platinum-based chemotherapy
    Nikolaidis, Christos
    Li, Chen
    Lee, Chooi
    Mecke, Almut
    Reyes-Rivera, Irmarie
    Schroder, Carsten
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 319 - 319
  • [39] Non-interventional Study of Avelumab in the Treatment of Urothelial Cancer - The AVENUE NIS - AB 82/21 of AUO First-line Maintenance Therapy in Adult Patients with locally advanced or metastatic Urothelial Cancer who are progression-free after platinum-based Chemotherapy
    不详
    UROLOGIE, 2023, 62 (06): : 672 - 673
  • [40] An open-label, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or with Standard Chemotherapy versus Standard Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO First-line Therapy for untreated, non-resectable or metastatic Urothelial Carcinoma
    Rexer, H.
    Retz, M.
    Waller, C.
    UROLOGE, 2018, 57 (07): : 880 - 881
12345